First Patient Treated Worldwide with the new TomoEDGE Dynamic Jaws Technology

Thu Apr 4, 2013 8:30am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130404:nPnSF88488

Heidelberg University Hospital pioneers use; providing precise and efficient
treatments
SUNNYVALE, Calif.,  April 4, 2013  /PRNewswire/ -- Accuray Incorporated (Nasdaq:
ARAY), announced today that Heidelberg University Hospital,  Germany, has
treated the world's first patients with the new TomoEDGE Dynamic Jaws technology
combined with  VoLO Planning  as part of its  TomoTherapy System. The new
TomoEDGE Dynamic jaws technology was introduced at ASTRO 2012 as the newest
evolution to the TomoTherapy System. The managing director of the department of
radiotherapy,  Jurgen Debus, M.D., and  Florian Sterzing, M.D., radiation
oncologist, both with Heidelberg University Hospital, were in charge of these
first treatments at Heidelberg University Hospital.  

"We treated our first patients on  March 25, 2013  using the TomoEDGE
technology, and we have successfully treated both prostate and breast patients,"
said  Florian Sterzing, M.D., radiation oncologist with Heidelberg University
Hospital. "With TomoEDGE we are now able to treat, faster, the entire spectrum
of the radiation oncology patients."

"With the new TomoEDGE technology, we can provide the most precise and
personalized treatment plans while also achieving significantly better dose
distributions and at the same time reduce overall treatment time," added  Jurgen
Debus, medical director of the department of radiation oncology and radiotherapy
with Heidelberg University Hospital.  

The new TomoEDGE technology allows for sharper dose sculpting and reduces
treatment time for many patients by approximately half, which will enable
clinics to treat more patients per day. TomoEDGE Dynamic Jaws are optimized to
open dynamically as they sweep across the target. This combines the benefits of
narrow jaw widths to better sculpt dose at the edges of the treatment volume
with larger jaw widths to complete treatment in a shorter time. The result is a
precise, yet faster and more customized treatment delivery that is as unique as
each patient.

The TomoTherapy System also includes the VoLO Technology a Graphics Processing
Unit (GPU)-based treatment planning which includes high-speed parallel
processing for both dose calculation and optimization. VoLO leverages advanced
graphics processing technology and a new calculation algorithm to significantly
reduce treatment planning time and flexibility in developing even the most
complex radiation therapy plans. Its speed allows users to explore a range of
parameter settings in a short time to maximize plan conformality, sparing of
normal tissues, and treatment efficiency.  

"We are committed to our TomoTherapy users and continue to innovate to provide
the most advanced treatments in radiation oncology with the goal of improving
patient care," said  Joshua H. Levine, president and chief executive officer of
Accuray. "We are proud that we have had the opportunity to collaborate with the
renowned Heidelberg University Hospital and are excited that they are the first
to see what TomoEDGE has to offer to the hospital, its physicians and their
patients. It will enable unprecedented speed and efficiency ensuring the highest
quality of care from the routine to the most complex cases."

About  Heidelberg University Hospital and  Department of Radiation Oncology

Internationally recognized patient care, research, and teaching - Heidelberg
University Hospital is one of the largest and most prestigious medical centers
in  Germany. The Medical Faculty of Heidelberg University belongs to one of the
most internationally renowned biomedical research institutions in  Europe. Both
institutions have the common goal of developing new therapies and implementing
them rapidly for patients. With about 11,000 employees, training and
qualification is an important issue. At the department of radiation oncology and
radiotherapy, the entire range of state-of-the-art radiation therapy diagnostics
and treatment is offered at the highest international level. Each year, more
than 4,000 cancer patients are treated at the department, which offers the full
range of up-to-date treatments.  

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact
are forward-looking statements and are subject to the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release relate, but are not limited, to clinical
applications, clinical results, patient outcomes, and the Company's leadership
position in radiation oncology innovation. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially from expectations, including risks detailed from time to time under
the heading "Risk Factors" in the company's report on Form 10-K filed on 
September 10, 2012, as updated in our Form 10-Qs filed on  November 8, 2012  & 
February 6, 2013, and as updated periodically by our other filings.
Forward-looking statements speak only as of the date the statements are made and
are based on information available to the Company at the time those statements
are made and/or management's good faith belief as of that time with respect to
future events. The Company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in assumptions or
changes in other factors affecting forward-looking information, except to the
extent required by applicable securities laws.  Accordingly, investors should
not place undue reliance on any forward-looking statements.

SOURCE  Accuray Incorporated


CONTACT : Anja Kleber, Marketing Director, Europe, + 33 (0) 1 55 23 20 20,
akleber@accuray.com, or Rebecca Phillips, Public Relations Manager, Accuray, +1
(408) 716-4773, rphillips@accuray.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.